Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 6858
  • Home
  • Print this page
  • Email this page
REVIEW ARTICLE
Year : 2016  |  Volume : 64  |  Issue : 1  |  Page : 4-13

Novel pharmacotherapies in diabetic retinopathy: Current status and what's in the horizon?


1 Department of Surgery, Division of Ophthalmology, University of New Mexico School of Medicine; Department of Surgery, New Mexico VA Health Care System; Department of Cell Biology and Physiology, University of New Mexico, Albuquerque, New Mexico, USA
2 Department of Cell Biology and Physiology, University of New Mexico, Albuquerque, New Mexico, USA
3 Department of Surgery, Division of Ophthalmology, University of New Mexico School of Medicine, Albuquerque, New Mexico, USA

Correspondence Address:
Arup Das
Department of Surgery, Division of Ophthalmology, University of New Mexico School of Medicine, MSC10-5610, 1 University of New Mexico, Albuquerque, New Mexico 87131
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0301-4738.178154

Rights and Permissions

The blood–retinal barrier (BRB) alteration is the hallmark feature of diabetic retinopathy. Vascular endothelial growth factor (VEGF) is a potent vasopermeability factor that has been implicated in the pathogenesis of BRB alteration. Inflammation also plays a crucial role in this process with involvement of several chemokines and cytokines. Multiple anti-VEGF drugs are widely used as in the treatment of diabetic macular edema (DME) as well as proliferative diabetic retinopathy. Several clinical trials have proved the beneficial effects of these drugs in improvement of vision and prevention of vision loss. However, the response to anti-VEGF drugs in DME is not complete in a significant number of patients. The effect seems transient in this latter group, and many patients do not show complete resolution of fluid. Potential novel therapies targeting molecules beyond VEGF are being developed and examined in clinical trials.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed4880    
    Printed43    
    Emailed0    
    PDF Downloaded886    
    Comments [Add]    

Recommend this journal